相关实验视频

Updated: Jun 9, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

抗血栓剂使用与肝细胞癌风险之间的关联:一个两样本的门德尔随机化分析

Fengyi Yang^1,2, Ouyang Li^3,4, Benjian Gao^1,2

¹Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Journal of cancer research and clinical oncology

|October 22, 2024

概括

抗血栓剂可以降低肝细胞癌 (HCC) 的风险,肝癌是一种常见的肝癌. 这项研究使用门德尔的随机化来调查因果关系,发现这些药物与较低的HCC风险相关的证据.

科学领域:

肝病学肝病学是一种肝病学.
在瘤学瘤学.
药物遗传学药物遗传学

背景情况:

肝细胞癌 (HCC) 是全球普遍存在的一种主要肝癌.
观察性研究表明抗血栓剂可能降低HCC风险,但因果关系未被证明.
门德尔随机化被用来研究抗血栓剂使用与HCC风险之间的因果关系.

研究的目的:

为了确定抗血栓剂使用对患肝细胞癌的风险的因果关系.
在孟德尔随机化框架中利用遗传变异作为抗血栓剂使用的仪器变量.

主要方法:

进行了两样本的孟德尔随机化分析.
使用了全基因组关联研究总结统计数据,用于欧洲裔个体的抗血栓剂使用.
逆方差加权 (IVW),加权中位数,MR-Egger和加权模式方法用于因果推断.
敏感性分析包括MR-PRESSO,MR-Egger,Cochran的Q测试和Leave-one-out分析以评估强度.

主要成果:

与使用抗血栓剂相关的10个单核酸多态 (SNP) 被确定为仪器变量.
所有应用的门德尔随机化方法都表明,抗血栓剂使用与HCC风险之间存在显著的反向因果关系.
在IVW方法中,该协会的赔率比为0.444 (95%CI:0.2790.707,P = 0.001).
没有检测到异质性或水平形的证据,支持发现的有效性.

结论:

这项研究提供了反向因果关系的证据,即抗血栓剂的使用与肝细胞癌的风险之间存在反向因果关系.
研究结果表明,抗血栓性药物对HCC发展具有潜在的保护作用.

关键词:

抗血栓剂抗血栓剂是一种抗血栓剂.因果关系是因果关系.肝细胞癌是肝细胞癌.门德尔的随机化研究.

更多相关视频

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...